Organogenesis Holdings Inc. Reports Third Quarter and Nine Months 2020 Financial Results
CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading…
Month: November 2020
Abeona Therapeutics Reports Third Quarter Financial Results
Conference call scheduled for Tuesday, November 10, 2020 at 8:30 a.m. ET NEW YORK and…
Homology Medicines Reports Third Quarter 2020 Financial Results and Recent Highlights
– Based on Positive Data, Advancing pheNIX Gene Therapy Clinical Trial for PKU to Dose…
Quotient Limited to Participate in Two Upcoming Conferences
JERSEY, Channel Islands, Nov. 09, 2020 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics…
Editas Medicine to Present at Barclays Gene Editing & Gene Therapy Summit
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a leading…
Novavax Reports Third Quarter 2020 Financial and Operational Results
Advanced clinical development of NVX‑CoV2373 with initiation of first Phase 3 trial to evaluate efficacy,…
Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million
Third Quarter 2020 Results: Record Revenue of $101.7 million, growing more than 880% year-over-year Record…
Progenity Provides Corporate Updates and Reports Third Quarter 2020 Financial Results
Reported 84 thousand tests in the third quarter, up 12% compared to the second quarter…
Novavax Appoints Gregory F. Covino as Chief Financial Officer and Announces Leadership Updates
Covino brings global biopharmaceutical finance experience to Novavax John Trizzino, Chief Business Officer, takes on…
Oncternal Therapeutics to Present at Stifel Virtual Healthcare Conference
SAN DIEGO, Nov. 09, 2020 (GLOBE NEWSWIRE) — Oncternal Therapeutics (Nasdaq: ONCT), today announced that…
Zogenix Provides Corporate Update and Reports Third Quarter 2020 Financial Results
FINTEPLA® (fenfluramine) oral solution launched in the U.S. in late July for Dravet syndrome with…
Affimed and Roivant Sciences Announce Licensing and Strategic Collaboration Agreement to Develop and Commercialize Novel Innate Cell Engagers (ICE®) for Multiple Cancer Targets
Affimed to grant license to AFM32 with options for additional ICE® molecules directed against…
First patient dosed with GLPG3667 in psoriasis patient Phase 1b trial
Mechelen, Belgium; 9 November 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces…
Kiniksa Announces American College of Rheumatology Convergence 2020 Late-Breaking Abstracts Presentation of Mavrilimumab Phase 2 Giant Cell Arteritis Data
Primary and secondary efficacy endpoints achieved statistical significance; mavrilimumab reduced risk of flare and increased…
Harrow Health Publishes Third Quarter 2020 Letter to Stockholders
NASHVILLE, Tenn., Nov. 09, 2020 (GLOBE NEWSWIRE) — Harrow Health, Inc. (NASDAQ: HROW) today reported…
Cerecor Reports Third Quarter 2020 Financial Results and Provides Business Update
On track to complete clinical trial for CERC-002 in cytokine storm-induced COVID-19 ARDS by year…
Cara Therapeutics Reports Third Quarter 2020 Financial Results
– Conference call today at 4:30 p.m. ET – STAMFORD, Conn., Nov. 09, 2020 (GLOBE…
Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported…
Inventiva to participate at the Stifel Virtual Healthcare Conference 2020 and the 11th Jefferies Virtual Healthcare Conference
Daix (France), November 9, 2020 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical…
Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC
– Data support continued development of ADP-A2M4CD8 – – On track to start Phase 2…